Report Detail
Global Recombinant Vaccines Market Insights, Forecast to 2025
- RnM2700500 |
- 17 June, 2019 |
- Global |
- 111 Pages |
- QYResearch |
- Pharma & Healthcare
Recombinant vaccines are produced using recombinant DNA technology, with the help of a vector. These vaccines stimulate the immune system of an individual and provide immunity against various lethal disease.
These vaccines are safe and have less or no side-effects as compared to conventional vaccines, in the prevention of various diseases such as influenza, cholera, typhoid, and dengue.
Recombinant vaccines are also used in animals for prevention of diseases such as foot and mouth disease, pneumonia and septicemia, and pox disease. Vaccination results in the prevention of disease, by producing antibodies against the protein antigen of pathogenic microorganisms.
There is increase in the demand for livestock products, which in turn has increased growth of the animal recombinant vaccine segment and Europe dominates the animal recombinant vaccines market as compared to other regions due to highly organized livestock and huge demand of livestock product for the European population.
The global Recombinant Vaccines market is valued at 880 million US$ in 2018 and will reach 1400 million US$ by the end of 2025, growing at a CAGR of 6.0% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Recombinant Vaccines market based on company, product type, end user and key regions.
This report studies the global market size of Recombinant Vaccines in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Recombinant Vaccines in these regions.
This research report categorizes the global Recombinant Vaccines market by top players/brands, region, type and end user. This report also studies the global Recombinant Vaccines market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Merck & Co., Inc
Green Cross Corporation
Pfizer Inc.
Bayer AG
Sanofi S A.
Protein Science Corporation
GlaxoSmithKline Plc.
Novartis AG
Bharat Biotech
Market size by Product
Subunit Recombinant Vaccines
Attenuated Recombinant Vaccines
Vector Recombinant Vaccines
Market size by End User
Recombinant Human Vaccines
Animal Recombinant Vaccines
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Recombinant Vaccines market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Recombinant Vaccines market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Recombinant Vaccines companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Recombinant Vaccines submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Recombinant Vaccines are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Recombinant Vaccines market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Recombinant Vaccines Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Recombinant Vaccines Market Size Growth Rate by Product
- 1.4.2 Subunit Recombinant Vaccines
- 1.4.3 Attenuated Recombinant Vaccines
- 1.4.4 Vector Recombinant Vaccines
- 1.5 Market by End User
- 1.5.1 Global Recombinant Vaccines Market Size Growth Rate by End User
- 1.5.2 Recombinant Human Vaccines
- 1.5.3 Animal Recombinant Vaccines
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Recombinant Vaccines Market Size
- 2.1.1 Global Recombinant Vaccines Revenue 2014-2025
- 2.1.2 Global Recombinant Vaccines Sales 2014-2025
- 2.2 Recombinant Vaccines Growth Rate by Regions
- 2.2.1 Global Recombinant Vaccines Sales by Regions
- 2.2.2 Global Recombinant Vaccines Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Recombinant Vaccines Sales by Manufacturers
- 3.1.1 Recombinant Vaccines Sales by Manufacturers
- 3.1.2 Recombinant Vaccines Sales Market Share by Manufacturers
- 3.1.3 Global Recombinant Vaccines Market Concentration Ratio (CR5 and HHI)
- 3.2 Recombinant Vaccines Revenue by Manufacturers
- 3.2.1 Recombinant Vaccines Revenue by Manufacturers (2014-2019)
- 3.2.2 Recombinant Vaccines Revenue Share by Manufacturers (2014-2019)
- 3.3 Recombinant Vaccines Price by Manufacturers
- 3.4 Recombinant Vaccines Manufacturing Base Distribution, Product Types
- 3.4.1 Recombinant Vaccines Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Recombinant Vaccines Product Type
- 3.4.3 Date of International Manufacturers Enter into Recombinant Vaccines Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Recombinant Vaccines Sales by Product
- 4.2 Global Recombinant Vaccines Revenue by Product
- 4.3 Recombinant Vaccines Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Recombinant Vaccines Breakdown Data by End User
6 North America
- 6.1 North America Recombinant Vaccines by Countries
- 6.1.1 North America Recombinant Vaccines Sales by Countries
- 6.1.2 North America Recombinant Vaccines Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Recombinant Vaccines by Product
- 6.3 North America Recombinant Vaccines by End User
7 Europe
- 7.1 Europe Recombinant Vaccines by Countries
- 7.1.1 Europe Recombinant Vaccines Sales by Countries
- 7.1.2 Europe Recombinant Vaccines Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Recombinant Vaccines by Product
- 7.3 Europe Recombinant Vaccines by End User
8 Asia Pacific
- 8.1 Asia Pacific Recombinant Vaccines by Countries
- 8.1.1 Asia Pacific Recombinant Vaccines Sales by Countries
- 8.1.2 Asia Pacific Recombinant Vaccines Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Recombinant Vaccines by Product
- 8.3 Asia Pacific Recombinant Vaccines by End User
9 Central & South America
- 9.1 Central & South America Recombinant Vaccines by Countries
- 9.1.1 Central & South America Recombinant Vaccines Sales by Countries
- 9.1.2 Central & South America Recombinant Vaccines Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Recombinant Vaccines by Product
- 9.3 Central & South America Recombinant Vaccines by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Recombinant Vaccines by Countries
- 10.1.1 Middle East and Africa Recombinant Vaccines Sales by Countries
- 10.1.2 Middle East and Africa Recombinant Vaccines Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Recombinant Vaccines by Product
- 10.3 Middle East and Africa Recombinant Vaccines by End User
11 Company Profiles
- 11.1 Merck & Co., Inc
- 11.1.1 Merck & Co., Inc Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Merck & Co., Inc Recombinant Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Merck & Co., Inc Recombinant Vaccines Products Offered
- 11.1.5 Merck & Co., Inc Recent Development
- 11.2 Green Cross Corporation
- 11.2.1 Green Cross Corporation Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Green Cross Corporation Recombinant Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Green Cross Corporation Recombinant Vaccines Products Offered
- 11.2.5 Green Cross Corporation Recent Development
- 11.3 Pfizer Inc.
- 11.3.1 Pfizer Inc. Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Pfizer Inc. Recombinant Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Pfizer Inc. Recombinant Vaccines Products Offered
- 11.3.5 Pfizer Inc. Recent Development
- 11.4 Bayer AG
- 11.4.1 Bayer AG Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Bayer AG Recombinant Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Bayer AG Recombinant Vaccines Products Offered
- 11.4.5 Bayer AG Recent Development
- 11.5 Sanofi S A.
- 11.5.1 Sanofi S A. Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Sanofi S A. Recombinant Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Sanofi S A. Recombinant Vaccines Products Offered
- 11.5.5 Sanofi S A. Recent Development
- 11.6 Protein Science Corporation
- 11.6.1 Protein Science Corporation Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Protein Science Corporation Recombinant Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Protein Science Corporation Recombinant Vaccines Products Offered
- 11.6.5 Protein Science Corporation Recent Development
- 11.7 GlaxoSmithKline Plc.
- 11.7.1 GlaxoSmithKline Plc. Company Details
- 11.7.2 Company Business Overview
- 11.7.3 GlaxoSmithKline Plc. Recombinant Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 GlaxoSmithKline Plc. Recombinant Vaccines Products Offered
- 11.7.5 GlaxoSmithKline Plc. Recent Development
- 11.8 Novartis AG
- 11.8.1 Novartis AG Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Novartis AG Recombinant Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Novartis AG Recombinant Vaccines Products Offered
- 11.8.5 Novartis AG Recent Development
- 11.9 Bharat Biotech
- 11.9.1 Bharat Biotech Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Bharat Biotech Recombinant Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Bharat Biotech Recombinant Vaccines Products Offered
- 11.9.5 Bharat Biotech Recent Development
12 Future Forecast
- 12.1 Recombinant Vaccines Market Forecast by Regions
- 12.1.1 Global Recombinant Vaccines Sales Forecast by Regions 2019-2025
- 12.1.2 Global Recombinant Vaccines Revenue Forecast by Regions 2019-2025
- 12.2 Recombinant Vaccines Market Forecast by Product
- 12.2.1 Global Recombinant Vaccines Sales Forecast by Product 2019-2025
- 12.2.2 Global Recombinant Vaccines Revenue Forecast by Product 2019-2025
- 12.3 Recombinant Vaccines Market Forecast by End User
- 12.4 North America Recombinant Vaccines Forecast
- 12.5 Europe Recombinant Vaccines Forecast
- 12.6 Asia Pacific Recombinant Vaccines Forecast
- 12.7 Central & South America Recombinant Vaccines Forecast
- 12.8 Middle East and Africa Recombinant Vaccines Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Recombinant Vaccines Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Recombinant Vaccines . Industry analysis & Market Report on Recombinant Vaccines is a syndicated market report, published as Global Recombinant Vaccines Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Recombinant Vaccines market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
